Dr. Lal Path Labs Ltd. has informed the Exchange about the incorporation of a Wholly Owned Subsidiary Company
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Lal PathLabs reported FY2026 consolidated revenue of INR 27,629 million, up 12.2% from INR 24,614 million in FY2025. Profit after tax grew to INR 5,098 million from INR 4,922 million, representing 3.6% PAT growth. The Board approved a final dividend of INR 4 per share (total annual dividend INR 20.5 per share), representing continued shareholder returns. Key corporate actions include acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited and incorporation of a new wholly-owned subsidiary Dr. Lal PathLabs FZCO in Dubai, UAE, expanding the company's international footprint. The Board also re-appointed Executive Chairman Dr. Arvind Lal and Independent Director Rajit Mehta, and designated two senior management personnel. Deloitte Haskins & Sells issued unmodified audit opinions on both standalone and consolidated financial results.
Strong operational performance with 12% revenue growth and consistent profitability. The Dubai subsidiary and domestic acquisition signal expansion strategy. Clean audit with unmodified opinion is positive for investor confidence. The 40% dividend payout demonstrates financial health.